Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

SPEGU vs ABUS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABUS Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 8–2 Matrix Metrics)

ABUS Overall Winner 6-Pillar Tally: SPEGU 0 – 6 ABUS Matrix Metrics: SPEGU 2 – 8 ABUS

As of Nov 20, 2026, Arbutus Biopharma Corporation (ABUS) is the stronger overall head-to-head candidate over Silver Pegasus Acquisition Corp Unit (SPEGU) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SPEGU carries a Unified Composite Score of 50.0/100 (HOLD) at $10.60 (N/M Forward P/E, N/A operating margin), whereas ABUS carries 43.4/100 (HOLD) at $4.02 (10.2x Forward P/E, 80.1% operating margin).

  • Composite vs. Pillar Nuance: While SPEGU currently prints a higher short-term Unified Composite Score (50.0/100 HOLD vs. ABUS 43.4/100 HOLD), ABUS captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (80.1% vs. N/A operating margin) and revenue trajectory (-43.5% vs. N/A YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SPEGU vs ABUS
SPEGU NASDAQ
Silver Pegasus Acquisition Corp Unit
Blank Checks
$10.60
+0.47% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.28β · 37% Vol
Unified Composite Score
50.0 / 100 HOLD
Tech 50.0 Fund 50.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Trend telemetry aligned with daily close.
RSI-14: N/A · SMA20: N/A · SMA50: N/A
ABUS NASDAQ Head-to-Head Winner
Arbutus Biopharma Corporation Common Stock
Pharmaceutical Preparations
$4.02
-1.23% 1D
Market Cap $623.9M
TTM Revenue $181M
Forward P/E 10.2x
Beta / 30D Vol 1.04β · 48% Vol
Unified Composite Score
43.4 / 100 HOLD
Tech 28.0 Fund 48.0 Flow 68.0 Mom 53.7
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.1 · SMA20: $4.02 · SMA50: $4.35

6-Pillar Scorecard Institutional Category Breakdown (SPEGU 0 – 6 ABUS)

Columns: Metric · SPEGU · ABUS
1. Valuation Multiples ABUS
Forward P/E N/M 10.2x
Trailing P/E N/M 3.6x
PEG Ratio N/M N/M
EV / Revenue N/M 2.0x
2. Growth & Scale ABUS
Revenue Growth (YoY) N/A -43.5%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $181M
Market Cap N/A $623.9M
3. Profitability & Quality ABUS
Gross Margin N/A 91.9%
Operating Margin N/A 80.1%
Net Profit Margin N/A 121.2%
Return on Equity (ROE) N/A 269.6%
4. Balance Sheet & Cash Flow ABUS
Cash Generation (TTM) N/A $221M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $264M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABUS
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 133.2% (18th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat ABUS
OpEx & R&D Intensity N/A 11.8% of Rev ($21M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Blank Checks Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SPEGU (2) vs ABUS (8)
Institutional Metric SPEGU ABUS Criterion Row Edge
Market Capitalization
Scale
N/A $623.9M Larger Scale ABUS
Trailing P/E Ratio
Valuation
N/M 3.6x Lower Multiple ABUS
Forward P/E Ratio
Valuation
N/M 10.2x Lower Multiple ABUS
Revenue Growth (YoY)
Growth
N/A -43.5% Higher Growth ABUS
Operating Margin (TTM)
Profitability
N/A 80.1% Higher Margin ABUS
Net Profit Margin
Profitability
N/A 121.2% Higher Margin ABUS
Return on Equity (ROE)
Capital Efficiency
N/A 269.6% Higher ROE ABUS
52-Week Range Position
Momentum
11% ($10–$14) 27% ($4–$5) Stronger Trend ABUS
Beta / 30D Volatility
Risk Regime
-0.28β · 37% Vol 1.04β · 48% Vol Lower Realized Risk SPEGU
Unified Institutional Score
Composite Signal
50.0 / 100 (HOLD) 43.4 / 100 (HOLD) Higher Composite SPEGU
Trailing 12M Revenue (USD)
Operating Scale
N/A $181M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 91.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 2.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) $221M ($264M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SPEGU +17.94 pp
SPEGU: +3.62% · ABUS: -14.32%
3M Horizon SPEGU +5.31 pp
SPEGU: +2.91% · ABUS: -2.4%
6M Horizon SPEGU +5.31 pp
SPEGU: +2.91% · ABUS: -2.4%
1Y Horizon SPEGU +5.31 pp
SPEGU: +2.91% · ABUS: -2.4%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SPEGU vs ABUS. Trailing 12-month operating profitability (SPEGU N/A vs ABUS 80.1%) and valuation multiples (SPEGU N/M vs ABUS 10.2x Forward P/E) are benchmarked directly in Pillar 4 below.

SPEGU ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
ABUS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$181M
Gross Margin91.9%
Op. Margin80.1%
ROE / Fwd P/E269.6% · 10.2x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SPEGU UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SPEGU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ABUS CONSOLIDATION
96d in phase · OBV ACCUMULATION
Current IV 133.2%
IV Percentile 18th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ABUS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SPEGU Moat Profile Cyclical / Execution-Driven Positioning
Blank Checks Operator
Competes within the Blank Checks value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ABUS Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $623.9M market capitalization and 80.1% operating margin.
OpEx & R&D Reinvestment 11.8% of Rev ($21M)
90D Engineering Disclosures 0 Published

Investor FAQ SPEGU vs ABUS Key Questions & Quantitative Answers

As of Nov 20, 2026, Arbutus Biopharma Corporation (ABUS) is the stronger overall head-to-head candidate over Silver Pegasus Acquisition Corp Unit (SPEGU) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SPEGU carries a Unified Composite Score of 50.0/100 (HOLD) at $10.60 (N/M Forward P/E, N/A operating margin), whereas ABUS carries 43.4/100 (HOLD) at $4.02 (10.2x Forward P/E, 80.1% operating margin). Composite vs. Pillar Nuance: While SPEGU currently prints a higher short-term Unified Composite Score (50.0/100 HOLD vs. ABUS 43.4/100 HOLD), ABUS captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (80.1% vs. N/A operating margin) and revenue trajectory (-43.5% vs. N/A YoY).

ABUS leads the Growth & Scale pillar: SPEGU posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABUS at -43.5% YoY revenue growth and +0.0% YoY earnings growth on $181M TTM revenue (91.9% gross margin, 80.1% operating margin). On trailing 12-month operating scale, SPEGU generates N/A in USD-normalized revenue versus $181M for ABUS. In operating R&D and SG&A reinvestment, SPEGU deploys N/A (0 90-day corporate R&D disclosures) versus 11.8% of Rev ($21M) (0 disclosures) for ABUS.

ABUS screens cheaper on headline valuation multiples. SPEGU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABUS trades at 10.2x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SPEGU (N/A ROE) versus ABUS (269.6% ROE) capital efficiency.

In options market volatility and institutional positioning, SPEGU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.28β · 37% Vol realized risk). By comparison, ABUS carries 133.2% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 48% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.